NYSE American - Delayed Quote • USD
Armata Pharmaceuticals, Inc. (ARMP)
At close: April 26 at 3:56 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Mina Pastagia M.D., MS | Chief Medical Officer | 537.6k | -- | 1975 |
Dr. Deborah L. Birx M.D. | CEO & Director | -- | -- | 1957 |
Mr. Richard Rychlik | VP, Corporate Controller & Principal Financial Officer | -- | -- | 1956 |
Mr. Peter Hubbard | Vice President of Operations | -- | -- | -- |
Dr. Pierre Kyme Ph.D. | Senior Vice President of Business & Corporate Development | -- | -- | -- |
Armata Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 66
Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
Corporate Governance
Armata Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 21, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 23, 2024S-8: Offering RegistrationsSee Full Filing
- Nov 15, 2023S-8: Offering RegistrationsSee Full Filing
Upcoming Events
May 09, 2024 - May 13, 2024
Armata Pharmaceuticals, Inc. Earnings Call
Related Tickers
INVA Innoviva, Inc.
15.26
+1.80%
PHGE BiomX Inc.
0.3500
+4.17%
GNFT Genfit S.A.
3.4900
+2.35%
SYBX Synlogic, Inc.
1.8700
-1.06%
ANEB Anebulo Pharmaceuticals, Inc.
2.7036
+1.26%
ANTX AN2 Therapeutics, Inc.
2.3200
+1.75%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
ARDS Aridis Pharmaceuticals, Inc.
0.0650
0.00%
ELDN Eledon Pharmaceuticals, Inc.
2.0600
+1.98%
AEON AEON Biopharma, Inc.
5.07
+19.29%